11:01 AM EDT, 03/31/2025 (MT Newswires) -- Vigil Neuroscience ( VIGL ) on Monday filed a registration statement for the resale of up to around 5.4 million shares, issuable upon conversion of about 538,000 shares of series A non-voting convertible preferred stock, from time to time by Aventis.

The company said it will not receive any proceeds from the sale of the shares as it is not selling the securities.

The selling stockholder bought the shares in a private placement on July 1, 2024, according to the filing.

Price: 1.80, Change: -0.11, Percent Change: -5.76